The drug SI-B001 represents a exciting step forward in the management of difficult-to-treat multiple myeloma. This first-in-class antibody selectively targets BCMA on myeloma cells, leading to BCMA-dependent cellular https://izalontamab-antibody605787.pointblog.net/izalontamab-si-b001-a-promising-emerging-immunoglobulin-approach-96130842